Real-World Data – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Mon, 22 Apr 2024 12:45:23 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Real-World Data – VJRegenMed https://mirror.vjregenmed.com 32 32 Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy https://mirror.vjregenmed.com/video/zsz-2br52sm-investigating-real-world-outcomes-of-patients-with-rr-lbcl-after-cd19-car-t-cell-therapy/ Thu, 26 Jan 2023 12:12:01 +0000 https://mirror.vjregenmed.com/video/zsz-2br52sm-investigating-real-world-outcomes-of-patients-with-rr-lbcl-after-cd19-car-t-cell-therapy/ Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]> Supporting the future of ATMPs in the EU https://mirror.vjregenmed.com/video/unbb3jxmkma-supporting-the-future-of-atmps-in-the-eu/ Sat, 10 Apr 2021 10:57:59 +0000 http://13.40.107.223/video/unbb3jxmkma-supporting-the-future-of-atmps-in-the-eu/ Paige Bischoff, Senior VP of Global Public Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., discusses the future of the policy and regulatory landscape for advanced therapy medicinal products (ATMPs) in the European Union (EU) and how ARM aims to support the sector’s growth in the coming years. She describes the importance of implementing innovative payment models for ATMPs in Europe and how the use of real-world evidence should be incorporated into health technology assessment (HTA) frameworks going forward. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]> The value of real-world data in the CAR-T field https://mirror.vjregenmed.com/video/_xh-miolw6s-the-value-of-real-world-data-in-the-car-t-field/ Fri, 26 Feb 2021 14:08:23 +0000 http://13.40.107.223/video/_xh-miolw6s-the-value-of-real-world-data-in-the-car-t-field/ Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the value of real-world data in the field of CAR T-cell therapies. Real-world data can provide much-added value and information compared with prospective data. Particularly in the CAR-T field, the multitude of different stakeholders requires additional, comprehensive information, including effectiveness in larger real-world populations. Therefore, real-world evidence can complement data from clinical trials to help inform clinicians, patients, regulatory agencies, and payers. Additionally, Prof. Mohty highlights how real-world data will help develop non only the CAR-T field but also cellular therapy in general. This interview took place during the 3rd European CAR T-cell Meeting.

]]> Real-world efficacy & safety data: CAR-T in DLBCL https://mirror.vjregenmed.com/video/9euabsoorr4-real-world-efficacy-safety-data-car-t-in-dlbcl/ Thu, 08 Oct 2020 14:08:13 +0000 http://13.40.107.223/video/9euabsoorr4-real-world-efficacy-safety-data-car-t-in-dlbcl/ Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory diffuse large B-Cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> Selecting DLBCL patients for CAR T-cell therapies https://mirror.vjregenmed.com/video/gr9xbcfrpsy-selecting-dlbcl-patients-for-car-t-cell-therapies/ Thu, 08 Oct 2020 14:08:11 +0000 http://13.40.107.223/video/gr9xbcfrpsy-selecting-dlbcl-patients-for-car-t-cell-therapies/ Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses how patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) are selected for CAR T-cell therapies and the associated challenges. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]>